Ipamorelin Research Hub — Selective GHRP Studies
Ipamorelin is a pentapeptide growth hormone secretagogue and selective agonist of the ghrelin (GHS-R1a) receptor. It is the most receptor-selective GHRP in the published research, notable for stimulating GH release without significantly elevating cortisol, prolactin or aldosterone.
What this hub covers
- Pentapeptide structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
- Selective ghrelin (GHS-R1a) receptor agonism
- Negligible cortisol and prolactin elevation vs hexarelin/GHRP-6
- Synergistic GH release with GHRH analogues
- Comparisons to other GHRPs (GHRP-2, GHRP-6, hexarelin)
Ipamorelin research articles
All research →Ipamorelin Research Overview
Ipamorelin: mechanism of action, receptor selectivity, GH pulse profile, and comparison to other GHRPs in research contexts.
Read article →Ipamorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and GHRP comparisons for ipamorelin — the most receptor-selective GHRP and standard partner for GHRH analogues.
Read article →Hexarelin Research Overview
Hexarelin: the most potent synthetic GHRP, its dual GH-releasing and GH-independent cardiac protection mechanisms, and the CD36 receptor pathway that sets it apart from all other GHRPs.
Read article →GHRP-2 Research Overview
GHRP-2 (Growth Hormone Releasing Peptide-2; Pralmorelin; KP-102) is a synthetic D-amino acid hexapeptide and high-efficacy GHS-R1a agonist — one of the most potent and thoroughly characterised growth hormone secretagogues in the research peptide class, studied in GH deficiency diagnosis, body composition research, and GH axis pharmacology across species.
Read article →GHRP-6 Research Overview
GHRP-6 (Growth Hormone Releasing Peptide-6; sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is the founding synthetic ghrelin mimetic hexapeptide — the compound that established the entire GHRP class, characterised the ghrelin receptor decades before ghrelin itself was identified, and remains uniquely studied for its pronounced appetite stimulation and cardioprotective properties.
Read article →CJC-1295 DAC vs No DAC: Research Overview
A research-context comparison of CJC-1295 with and without the Drug Affinity Complex modification — pharmacokinetics, GH secretion patterns, and the implications for pulsatility.
Read article →CJC-1295 Benefits and Side Effects: A Research Guide
Published benefits, side effects, and DAC vs no-DAC comparisons for CJC-1295 — the stabilized GHRH(1-29) analog with two distinct research profiles.
Read article →Ipamorelin research FAQ
- Why is ipamorelin considered the most selective GHRP?
- Unlike hexarelin and GHRP-6, ipamorelin's binding profile is essentially confined to the ghrelin receptor (GHS-R1a). Published models report GH release comparable to other GHRPs with minimal effect on cortisol, prolactin or aldosterone.
- Why is ipamorelin paired with CJC-1295 or sermorelin in research?
- GHRH analogues and GHRPs act on independent pituitary receptors, producing synergistic GH release when combined. The combination is one of the most replicated stacks in GH-axis research.
- How does ipamorelin compare to GHRP-2 and GHRP-6?
- All three are ghrelin receptor agonists, but GHRP-2 and GHRP-6 also elevate cortisol/prolactin (GHRP-6 additionally stimulates appetite via central pathways). Ipamorelin is the cleanest of the three for studies focused purely on GH release.
- How is ipamorelin stored?
- Lyophilized ipamorelin is stable at 2–8 °C protected from light. After reconstitution with bacteriostatic water, refrigerate and use within the COA's documented window.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.